References
- Werner RN, Sammain A, Erdmann R, et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18.
- Stockfleth E, Kerl H. Guideline subcommittee of the European dermatology forum. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16:599–606.
- de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222–30.
- Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol. 2008;18:651–9.
- Rossi R, Calzavara-Pinton PG, Giannetti A, et al. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol. 2009;144:713–23.
- Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis – international league of dermatological societies in cooperation with the European dermatology forum – short version. J Eur Acad Dermatol Venereol. 2015;29:2069–79.
- Peserico A, Neri L, Calzavara Pinton P, et al. Key opinion leader (KOL) consensus for actinic keratosis management in Italy: the AKTUAL workshop. G Ital Dermatol Venereol. 2013;148:515–24.
- Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–19.
- Lebwohl M, Shumack S, Stein Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149:666–70.
- Jubert-Esteve E, Del Pozo-Hernando LJ, Izquierdo-Herce N, et al. Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study. Actas Dermosifiliogr. 2015;106:644–50.
- Olsen EA, Abernethy ML, Kulp-Shorten C, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1;24:738–43.
- Gupta AK, Paquet M. Network meta-analysis of the outcome 'participant complete clearance' in non-immunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013;169:250–9.
- Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014;9:e96829.
- Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adher. 2013;8:35–41.
- Erntoft S, Norlin J, Pollard C, Diepgen TL. Patient adherence and non-persistence behaviour in real life actinic keratosis (Ak) topical treatment in the UK, Germany and France. Value Health. 2014;17:A287.
- Gwadry-Sridhar FH, Manias E, Lal L, et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health. 2013;16:863–71.
- Stockfleth E, Peris K, Guillen C, et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol. 2015;54:509–15.
- Peris K, Neri L, Calzavara Pinton PG, et al. Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy. G Ital Dermatol Venereol. 2014;149:185–92.
- Callender VD, Preston N, Osborn C, et al. A meta-analysis to investigate the relation between Fitzpatrick skin types and tolerability of adapalene-benzoyl peroxide topical gel in subjects with mild or moderate acne. J Clin Aesthet Dermatol. 2010;3:15–9.
- Bettencourt MS. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice. J Drugs Dermatol. 2014;13:269–73.